Last reviewed · How we verify

Adenovite (ADENOSINE PHOSPHATE)

FDA-approved withdrawn Small molecule Quality 20/100

Adenovite, a marketed drug by an unspecified company, activates adenosine receptors to treat cystic fibrosis of the lung. Its key strength lies in its mechanism of reducing inflammation and slowing disease progression, setting it apart in the treatment landscape. The primary risk is the competition from disulfiram, an off-patent drug with the same target, which may limit Adenovite's market share.

At a glance

Generic nameADENOSINE PHOSPHATE
Drug classAdenosine Receptor Agonist
TargetProto-oncogene tyrosine-protein kinase Src
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: